Trazonil: Compound Profile
Trazonil 100 mg is a pharmaceutical preparation of trazodone hydrochloride manufactured by Intas Pharmaceuticals. Trazodone is a triazolopyridine derivative antidepressant compound that serves as a valuable research tool for investigating serotonin receptor modulation, sleep architecture, and neurochemical pathways in laboratory studies. This pharmaceutical-grade formulation enables researchers to examine the compound’s multifaceted mechanism of action, which includes serotonin reuptake inhibition, alpha-1 adrenergic receptor antagonism, and histamine H1 receptor blocking properties. The standardised 100 mg tablet format provides consistent dosing parameters for controlled experimental protocols. Researchers at Stroid UK Shop utilise this compound to study its unique pharmacological profile that distinguishes it from conventional selective serotonin reuptake inhibitors.
Laboratory Applications
In research environments, Trazonil tablets facilitate investigations into sleep-wake cycle regulation, as trazodone demonstrates significant effects on sleep architecture through its antagonism of alpha-1 adrenergic and histamine receptors. Studies examining circadian rhythm disturbances often employ trazodone as a reference compound due to its sedating properties and minimal impact on REM sleep patterns. The compound’s dual mechanism as both a weak serotonin reuptake inhibitor and potent 5-HT2A receptor antagonist makes it valuable for research into depression models and serotonergic neurotransmission. Researchers investigating cardiovascular effects utilise trazodone to study its impact on cardiac conduction and blood pressure regulation through alpha-adrenergic pathways. The pharmaceutical preparation from Intas ensures consistent bioavailability parameters across experimental protocols. Scientists exploring other pharmaceutical compounds often compare results against trazodone’s established pharmacological profile.
Technical Specifications
| Parameter | Value |
|---|---|
| Active Ingredient | Trazodone Hydrochloride |
| Strength | 100 mg per tablet |
| Manufacturer | Intas Pharmaceuticals |
| Formulation | Immediate-release tablet |
| CAS Number | 19794-93-5 (trazodone HCl) |
| Molecular Formula | C₁₉H₂₂ClN₅O·HCl |
| Storage Requirements | Room temperature, dry conditions |
| Research Applications | Sleep studies, serotonin research, cardiovascular effects |
The pharmaceutical-grade quality ensures reproducible experimental conditions for researchers studying neuropharmacological mechanisms. Unlike research chemicals available through selective androgen receptor modulators or peptide research categories, these tablets provide standardised pharmaceutical consistency essential for comparative studies and regulatory research protocols.
Research Compliance
Trazonil 100 mg tablets are supplied exclusively for legitimate laboratory research purposes and in-vitro studies. This pharmaceutical preparation is not intended for human consumption, veterinary use, or any therapeutic applications. Researchers must maintain appropriate licensing and institutional oversight when conducting studies with this compound. All experimental protocols should comply with relevant research guidelines and safety regulations governing pharmaceutical research materials. Storage should follow pharmaceutical standards to maintain compound stability and research integrity throughout study periods.
